Jupiter Endovascular Hires Fred Ong as Finance Chief

Jupiter Endovascular revealed that experienced medtech finance and operations exec Fred Ong has joined the company as chief financial officer (CFO).

Ong touts over three decades of experience in building and growing venture capital-backed healthcare tech companies. He has been CFO of Sirona Medical since 2020, and was also finance chief at Datavant and U-Systems. He was also critical in the successful exits of several companies by acquisition and merger with larger strategics.

“I’m thrilled to join the Jupiter Endovascular team as they continue to execute on their mission to transform endovascular therapy with their groundbreaking transcatheter technology,” said Ong. “It is exciting to see their early clinical success in addressing pulmonary embolism, and the enormous potential of this technology to meaningfully improve the physician experience and patient outcomes. I look forward to playing a role in advancing the company from its current clinical stage through commercialization. With a strong and expanding base of intellectual property, there is tremendous opportunity across a variety of disease conditions and procedures to grow applications for the technology into the future.”

Jupiter Endovascular’s Endoportal Control platform was designed for greater ease and stability to a variety of catheter interventions. Its goal is to allow interventionalists to treat anatomical sites that they can’t safely or easily reach with a conventional endovascular approach.

The endoportal device is delivered in a flexible, relaxed configuration over a guidewire to a target area in the vasculature, pressurized with saline to fix it in a stable position for therapeutic delivery. It’s then relaxed again to navigate to another target location or for removal.

“We are delighted to welcome Fred to Jupiter, and look forward to his significant contribution to the company’s success moving forward,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “Fred is joining us at a pivotal time as we build upon our strong clinical momentum in pulmonary embolism and continue to grow, expand, and prepare for what we believe is a robust commercial opportunity for our transformational technology.”

In the past few months, the company started enrolling patients in a U.S. pivotal study for acute, intermediate-risk pulmonary embolism. Jupiter exited stealth mode in August 2024, with $21 million in financing.